Back to Awarded Treatment Trials
Awarded Trial: 02T-119
Grant ID
02T-119
Illness
Schizophrenia
Primary Drug/Intervention
Amridin
Primary Dosage
60-120mg
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Morozova
Sample Size
60
Duration of Study Period for Each Subject
10 months
Outcome Measurements
Cognitive battery, PANSS, CGI
Results
Amridin is a reversible cholinesterase inhibitor, muscarinic M1 + M3 antagonist and M2 partial agonist. At higher doses the drug also inhibits MAO-B. Patients who had been receiving risperidone therapy for at least 4 weeks, were randomized to receive amridin or placebo as adjunctive therapy in a 2:1 ratio. There were subtle but significant benefits for amiridin on PANSS positive, PANSS negative, CGI and several cognitive tests.
Publication
N/A
Link
N/A
PI Name
Margarita Morozova
Degree
MD
Center
Mental Health Research Center
Institution
Russian Academy of Medical Sciences
Address
Zagorodnoe Shosse 2, korp. 2
City or Town
Moscow
State or Province
N/A
Zip or Postal Code
113152
Country
Russia
Email Address
m_morozova01@mail.ru